Intact Vascular said yesterday that it named medical device veteran Bruce Shook as its new president & CEO.
Shook spent 11 years at Neuronetics, the neuromodulation company he co-founded and led as president & chief executive, according to a press release. Shook also co-founded Neuron Therapeutics, a drug/device company in the central nervous system space, according to the release, and was president of Abiomed (NSDQ:ABMD). His résumé includes a stint at Cordis Corp., now a Johnson & Johnson (NYSE:JNJ) subsidiary.
"We are delighted to have Bruce at the helm. His wealth of successful operational experience in medical device companies is a prerequisite to expedite Intact’s growth to the next level of both product and clinical development," Intact Vascular chairman Dr. Dennis Wahr said in prepared remarks.
"I am very impressed with what the Intact Vascular team has accomplished. They have developed an extraordinarily innovative approach to the treatment of peripheral vascular disease that holds significant promise to advance endovascular therapy beyond the current practice of stenting. Intact has exceptional assets and I am truly excited to be working with this team to improve patient care, offer customers novel solutions, and build value for our stakeholders," Shook added.
Spiracur taps ex-KCI prez Fashek as CEO
Spiracur said it named former Kinetic Concepts Inc. president & vice-chairman Chris Fashek – who’s already the negative-pressure wound therapy firm’s chairman – as its new president & CEO.
Philips Dunlee shuffles the deck
Pat Fitzgerald, the former president of Philips Healthcare‘s (NYSE:PHG) Dunlee division, is stepping down to pursue other interests, DotMED reported. Mark Szewczyk was promoted general manager of Dunlee’s Aurora, Ill., site and Laura Hafner was promoted from director of global marketing to the leadership role for Dunlee’s GTC Third Party business.